Noile-Immune Biotech (TSE:4893) FCF Margin %: 0.00% (As of Dec. 2025)


TSE:4893 Noile-Immune Biotech Inc TSE:4893
53 GF Score
Price 円120.00
GF Value 円4.38
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Noile-Immune Biotech FCF Margin %?

Noile-Immune Biotech TSE:4893 +0.84% 53 FCF Margin % is 0.00% as of Dec. 2025. GuruFocus rates TSE:4893 with a GF Score™ of 53/100 and a GF Value™ of 円4.38 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, Noile-Immune Biotech ranks worse than 96.87% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Noile-Immune Biotech's Free Cash Flow for the three months ended in Dec. 2025 was 円0.00 Mil. Noile-Immune Biotech's Revenue for the three months ended in Dec. 2025 was 円0.00 Mil. Therefore, Noile-Immune Biotech's FCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Noile-Immune Biotech's current FCF Yield % is -14.48%.

The historical rank and industry rank for Noile-Immune Biotech's FCF Margin % or its related term are showing as below:

TSE:4893' s FCF Margin % Range Over the Past 10 Years
Min: -35101.21   Med: -540.28   Max: -17.13
Current: -35101.21

During the past 6 years, the highest FCF Margin % of Noile-Immune Biotech was -17.13%. The lowest was -35101.21%. And the median was -540.28%.

TSE:4893's FCF Margin % is ranked worse than
96.87% of 959 companies
in the Biotechnology industry
Industry Median: -84.65 vs TSE:4893: -35101.21

Noile-Immune Biotech FCF Margin % Related Terms

Noile-Immune Biotech FCF Margin % Historical Data

* Premium members only.

The historical data trend for Noile-Immune Biotech's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Noile-Immune Biotech FCF Margin % Chart

Noile-Immune Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial -771.49 -17.13 -275.58 -11,701.71 -15,044.38

Noile-Immune Biotech Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TSE:4893 vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, Noile-Immune Biotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Noile-Immune Biotech FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Noile-Immune Biotech's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Noile-Immune Biotech's FCF Margin % falls into.


TSE:4893
53GF Score
Noile-Immune Biotech Inc TSE:4893
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Noile-Immune Biotech FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Noile-Immune Biotech's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-752.219/5
=-15,044.38 %

Noile-Immune Biotech's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=0/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Noile-Immune Biotech (TSE:4893) has a FCF Margin % of 0.00% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Noile-Immune Biotech and its competitors. According to the industry distribution chart, Noile-Immune Biotech ranks #929 out of 959 companies in the Biotechnology industry, placing it in the top 96.9%.
Is Noile-Immune Biotech's FCF Margin % too high?
Noile-Immune Biotech's current FCF Margin % is 0.00%. Based on the distribution chart, Noile-Immune Biotech ranks #929 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Noile-Immune Biotech has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noile-Immune Biotech's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Noile-Immune Biotech ranks #929 out of 959 companies for FCF Margin %. This places Noile-Immune Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Noile-Immune Biotech and its competitors. Noile-Immune Biotech's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noile-Immune Biotech stock overvalued right now?
Based on GuruFocus' analysis, Noile-Immune Biotech (TSE:4893) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.38, compared to a current price of 円120.00 — trading 2639.7% above its estimated fair value. The current FCF Margin % is 0.00%. Noile-Immune Biotech's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Noile-Immune Biotech (TSE:4893), the current FCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Noile-Immune Biotech (TSE:4893) Overvalued in 2026?

Based on GuruFocus' analysis, Noile-Immune Biotech stock appears to be overvalued. The current stock price of 円120.00 is trading 2639.7% above its estimated GF Value™ of 円4.38. GuruFocus considers Noile-Immune Biotech to be Significantly Overvalued.

Key valuation signals for TSE:4893:

  • FCF Margin %: 0.00%
  • GF Value™: 円4.38 vs. price of 円120.00 (2639.7% above fair value)
  • GF Score™: 53/100 with 2 warning signs

No single metric tells the full story. See the TSE:4893 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Noile-Immune Biotech Business Description

Address 2-12-10 Shiba-Daimon, 5th Floor, T&G Hamamatsucho Building, Minato-ku, Yamaguchi, Tokyo, JPN, 105-0012
Noile-Immune Biotech Inc is engaged in the development of CAR-T cell therapy for solid cancers using its proprietary technology. The company's development pipeline and collaborative projects with other companies include different product candidates such as NIB102, NIB103, NIB104, ADAP01, AUTL01, etc. It operates in a single segment, the cancer immunotherapy drug discovery business.
53GF Score

Get the complete analysis for TSE:4893

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円120.00
Price
円4.38
GF Value